131I全身显像在分化型甲状腺癌中的临床应用 现状与前景
Current Status and Prospects of Clinical Application of 131I Whole-Body Scan in Differentiated Thyroid Cancer
DOI: 10.12677/acm.2026.1641630, PDF,   
作者: 明庭辉：西安医学院研究生处，陕西 西安；空军军医大学第一附属医院核医学科，陕西 西安；马温惠*：空军军医大学第一附属医院核医学科，陕西 西安
关键词: 分化型甲状腺癌；131I治疗；131I全身显像；Differentiated Thyroid Cancer； 131I Therapy； 131I Whole-Body Scan
摘要: 甲状腺癌发病率增长最快，是内分泌系统最常见的恶性肿瘤。尽管分化型甲状腺癌预后较好，但仍有部分患者存在转移性病变，早期发现是提高患者生存率的关键。颈部超声与CT在鉴别良恶性、显示深部淋巴结等方面存在局限。131I全身显像可对分化型甲状腺转移灶特异性显像，实现精准定位与定性，有助于临床分期、复发风险分层及治疗管理。本文就131I全身显像的原理、分类、临床应用及研究进展进行综述。
Abstract: The incidence of thyroid cancer is increasing the fastest and it is the most common malignant tumor in the endocrine system. Although differentiated thyroid cancer has a better prognosis, there are still some patients with metastatic lesions. Early detection is the key to improving the survival rate of patients. Neck ultrasound and CT have limitations in differentiating benign and malignant lesions and showing deep lymph nodes. 131I whole-body scan can specifically image differentiated thyroid metastases, achieving precise localization and qualitative assessment, which is helpful for clinical staging, risk stratification of recurrence and treatment management. This article reviews the principle, classification, clinical application and research progress of 131I whole-body scan.
文章引用：明庭辉, 马温惠. 131I全身显像在分化型甲状腺癌中的临床应用 现状与前景[J]. 临床医学进展, 2026, 16(4): 3662-3666. https://doi.org/10.12677/acm.2026.1641630

参考文献

[1] Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. [Google Scholar] [CrossRef] [PubMed]
[2] Heston, T.F. and Wahl, R.L. (2010) Molecular Imaging in Thyroid Cancer. Cancer Imaging, 10, 1-7.
[3] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2021版) [J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.
[4] Rondeau, G., Fish, S., Hann, L.E., Fagin, J.A. and Tuttle, R.M. (2011) Ultrasonographically Detected Small Thyroid Bed Nodules Identified after Total Thyroidectomy for Differentiated Thyroid Cancer Seldom Show Clinically Significant Structural Progression. Thyroid, 21, 845-853. [Google Scholar] [CrossRef] [PubMed]
[5] 李亚敏, 章斌. 123I及其标记化合物在核医学中的应用进展[J]. 国际放射医学核医学杂志, 2024, 48(10): 631-636.
[6] Dai, G., Levy, O. and Carrasco, N. (1996) Cloning and Characterization of the Thyroid Iodide Transporter. Nature, 379, 458-460. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, Q. and Xu, W. (2022) Correlation Analysis of I-131 SPECT/CT Uptake Parameters with the Success Ablation Treatment of Thyroid Remnant in Patients with Low-Intermediate-Risk Differentiated Thyroid Cancer. Nuclear Medicine Communications, 43, 1051-1057. [Google Scholar] [CrossRef] [PubMed]
[8] Arnstein, N.B., Carey, J.E., Spaulding, S.A., et al. (1986) Determination of Iodine-131 Diagnostic Dose for Imaging Metastatic Thyroid Cancer. Journal of Nuclear Medicine, 27, 1764-1769.
[9] Ran, B., Shang, J., Chen, Y., Zhou, M., Li, H., He, W., et al. (2024) The Value of the First Postoperative Diagnostic I-131 Scan in Patients with Papillary Thyroid Carcinoma. Journal of Cancer Research and Clinical Oncology, 150, Article No. 80. [Google Scholar] [CrossRef] [PubMed]
[10] 姜晓彤, 刘锦川, 张迎强, 等. 诊断性131I全身显像在分化型甲状腺癌131I治疗决策中的作用[J]. 中国癌症杂志, 2025, 35(1): 77-84.
[11] Avram, A.M., Esfandiari, N.H. and Wong, K.K. (2015) Preablation 131-I Scans with SPECT/CT Contribute to Thyroid Cancer Risk Stratification and 131-I Therapy Planning. The Journal of Clinical Endocrinology & Metabolism, 100, 1895-1902. [Google Scholar] [CrossRef] [PubMed]
[12] Avram, A.M., Giovanella, L., Greenspan, B., et al. (2022) SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. Journal of Nuclear Medicine, 63, 15n-35n.
[13] Lin, Y., Wen, Q., Fu, W., Yang, H., Gao, Y., Li, Z., et al. (2025) Rhtsh in Aiding Dynamic Assessment in Patients with Differentiated Thyroid Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53, 389-397. [Google Scholar] [CrossRef] [PubMed]
[14] 徐雨彤, 吴江, 陈君, 等. 安罗替尼抑制甲状腺癌进展并诱导其再分化的实验研究[J]. 中华核医学与分子影像杂志, 2025, 45(4): 229-233.
[15] Weis, H., Weindler, J., Schmidt, K., Hellmich, M., Drzezga, A. and Schmidt, M. (2025) Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories. Journal of Nuclear Medicine, 66, 525-530. [Google Scholar] [CrossRef] [PubMed]
[16] Miller, J.E., Al-Attar, N.C., Brown, O.H., Shaughness, G.G., Rosculet, N.P., Avram, A.M., et al. (2018) Location and Causation of Residual Lymph Node Metastasis after Surgical Treatment of Regionally Advanced Differentiated Thyroid Cancer. Thyroid, 28, 593-600. [Google Scholar] [CrossRef] [PubMed]
[17] Ciappuccini, R., Heutte, N., Trzepla, G., Rame, J., Vaur, D., Aide, N., et al. (2011) Postablation 131I Scintigraphy with Neck and Thorax SPECT-CT and Stimulated Serum Thyroglobulin Level Predict the Outcome of Patients with Differentiated Thyroid Cancer. European Journal of Endocrinology, 164, 961-969. [Google Scholar] [CrossRef] [PubMed]
[18] Chong, A., Seo, Y., Bang, J., Park, S., Kim, K., Hong, C.M., et al. (2023) Clinical Implications of Adding SPECT/CT to Radioiodine Whole-Body Scan in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Clinical Nuclear Medicine, 49, 215-225. [Google Scholar] [CrossRef] [PubMed]
[19] Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., et al. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26, 1-133. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, S., Zuo, R., Yang, T., Pang, H. and Wang, Z. (2022) A Semiquantitative Study of the Optimal Whole-Body Imaging Time after (131)I Therapy for Differentiated Thyroid Cancer. Frontiers in Endocrinology, 13, Article ID: 955387. [Google Scholar] [CrossRef] [PubMed]
[21] Salvatori, M., Perotti, G., Villani, M.F., Mazza, R., Maussier, M.L., Indovina, L., et al. (2013) Determining the Appropriate Time of Execution of an I-131 Post-Therapy Whole-Body Scan: Comparison between Early and Late Imaging. Nuclear Medicine Communications, 34, 900-908. [Google Scholar] [CrossRef] [PubMed]

为你推荐